A Phase II, Single Arm, Open label Study of Cyclophosphamide, Vincristine, Liposomal Doxorubicine (Myocet?) and Prednisone plus Rituximab in Fortnightly Regimen (R-COMP-14), as First Line of therapy for Patients with Aggressive Non Hodgkin's Lymphoma (NHL).
ESTADO CLÍNICO
En marcha
FASE/S DEL ENSAYO
Fase IV
PATOLOGÍA
Linfoma Hodgkin, Linfoma no Hodgkin, Terapia celular y T-CARs, Linfoma
FECHA DE APERTURA
Abril, 2010
FECHA DE CIERRE
,
CRITERIOS DE INCLUSIÓN
Dose-dense modified R-CHOP regimen (R-COMP) in patients with aggressive NHL.
CRITERIOS DE EXCLUSIÓN
No especificado
DESCRIPCIÓN
To evaluate antitumoral activity expressed as overall response rate in patients with agressive non-Hodgkin's lymphoma treated with R-COMP and bone marrow support every 14 days.
PALABRAS CLAVE
cd20, dlbcl, hodgkin, hodgkin lymphoma, lymphoma, non-hodgkin lymphoma
